Enhancing the specificity of prostate-specific antigen (PSA): An overview of PSA density, velocity and age-specific reference ranges

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 61-67

  Nixon, R G ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN SPECIFICITY; BLOOD LEVEL; CONFERENCE PAPER; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0031397329     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00803.x     Document Type: Article

References (43)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. 1995. CA Cancer J Clin 1995; 45: 8-30
2. Brawer MK, Ellis WJ. Chemoprevention for prostatic carcinoma. Cancer 1995; 75: 1783-9
3. Wilt TJ, Brawer MK. The prostate cancer intervention vs. observation trial. A randomized trial comparing radical prostatectomy vs. expectant management for the traetment of clinically localized prostate cancer. J Urol 1994; 152: 1910-14
4. Mettlin C, Jones G. Averett H et al. Defining and updating the American Cancer Society guidelines for the cancerrelated checkup. Prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-6
5. American Urological Association Policy Statement. Early Detection of Prostate Cancer and Use of Titransrectal Ultrasound. Baltimore, American Urological Association 1992 Policy Statement Book, 1992: 4.20
6. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. NewEngl J Med 1987; 317: 909-16
7. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991; 324: 1156-61
8. Brawer MK, Chetner MP, Beatie J et al Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-5
9. Catalona Wj, Smith DS, Ratliff TL et al Detection of organconfined prostate cancer is increased through prostatespecific antigen-based screening. JAMA 1993; 270: 948-54
10. Jacobsen SJ, Katusic SK, Bergstralh Ej et al Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274: 1445
11. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
12. Littrup PJ, Kane RA, Mettlin CJ et al Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Cancer 1994; 74: 3146-58
13. Babaian RJ, Pritsche HA, Evans RB. Prostate-specific antigen and the prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990; 4: 135-7
14. Benson MC, Whang IS, Pantuck A et al Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-16
15. Benson MC, Whang IS, Olsson CA et al The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21
16. Seaman E, Whang M, Olsson CA et al. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993; 20: 653-63
17. Brawer MK, Aramburu BAG, Chen GL et al The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369-73
18. Bazinet M, Meshref AW, Trudel C et al Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994; 43: 44-51
19. Rommel FM, Agusta VE, Breslin JA et al The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J UroJ 1994; 151: 88-93
20. Mettlin CM, Littrup PJ, Kane RA et al Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA. PSA density, and PSA change. Cancer 1994; 74: 1615-20
21. Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995; 46: 666-71
22. Littrup PJ, Kane RA, Mettlin CJ et al Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Cancer 1994; 74: 3146-58
23. Bangma CH, Kranse R, Blijenberg BG et al The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773-8
24. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2-12
25. Henderson RJ, Eastham JA, Culkin DJ et al Prostate specific antigen (PSA) and PSA density (PSAD) are higher in African Americans without prostate cancer: results of 526 patients. J Urol 1996; 155 (Suppl.): 262A
26. Hovey RM, Shinohara K, Bhargava V et al. Prostate specific antigen and prostate specific antigen density in the detection of prostate cancer: ethnic variations. J Urol 1996: 155 (Suppl.): 267A
27. McCammon KA, Schellhammer PF, Wright GL et al. Age specific PSA levels in African Americans. J Urol 1996: 155 (Suppl.): 461A
28. Carter HB, Morrel CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-8
29. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J UroL 1994; 152: 1163-7
30. Brawer MK, Beatie J, Wener MH et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993; 150: 106-9
31. Porter JR, Hayward R, Brawer MK. The significance of short-term PSA change in men undergoing ultrasoundguided prostate biopsy. J Urol 1994; 151 (Suppl.): 293A.
32. Catalona WJ, Smith DS, Ratliff TL. Value of measurements of the rate of change of serum PSA levels in prostate cancer screening. J UroL 1993; 149 (Suppl.): 300A.
33. Nixon RG, Wener MH. Smith KM et al. Biological variation of prostate-specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997, in press
34. Carter HB, Pearson JD, Chan DW et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995: 45: 591-6
35. Oesterling JE, Jacobsen SJ. Chute et al. Serum prostatespecific antigen in a community-based population of healthy men. JAMA 1993; 270: 860-4
36. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Vrol 1993: 150: 1837-9
37. Oesterling JE, Cooner WH, Jacobsen SJ et al. Influence of patient age on the serum PSA concentration, an important clinical observation. Vrol Clin North Am 1993; 20: 671-80
38. El-Galley RES, Petros JA, Sanders WH et al. Normal range prostate-specific antigen vs. age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 1995:46: 200-4
39. Reissigl A, Pointner J, Horninger W et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology 1995: 46: 662-5
40. Pettaway J, Brawer MK. Age specific vs. 4.0 ngJmL as PSA cutoff in the screening population. J Urol 1995; 153 (Suppl.): 946A
41. Borer JG, Serman J, Solomon MC et al. Age-specific reference ranges for prostate specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures. J Urol 1996; 155 (Suppl.): 48A
42. Scher HI, Fosså S. Prostate cancer in the era of prostatespecific antigen. Curr Opin Oncol 1995; 7: 281-9
43. Potosky AL, Miller BA, Albertsen PC et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995: 273: 548-52